X4 Pharmaceuticals(XFOR)
BOSTON, MAPharmaceutical
Focus: X4 Pharmaceuticals is a Boston-based public biotech focused on oral small molecules for immunology and oncology, with a pipeline anchored on two lead programs in Phase 2/3 development.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at X4 Pharmaceuticals?
AI assessmentX4 is a clinical-stage biotech with meaningful pipeline optionality but acute cash constraints and minimal hiring—suitable only for risk-tolerant scientists seeking Phase 3 catalyst exposure, not career stability.
Why Work Here
- Lead programs (Mavorixafor for WHIM Syndrome and Neutropenia) in Phase 3 with potential 2029 FDA approval, creating near-term catalyst visibility.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
No intervention
WHIM SyndromeClinical Trials (1)
NCT03087370A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
N/AHelp build intelligence for X4 Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.